Press Release: Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
– Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful reductions in blood pressure in participants with chronic kidney disease – – In participants with chronic kidney disease and baseline albuminuria, lorundrostat significantly reduced urine albumin-to-creatinine ratio –
ORION CORPORATION PRESS RELEASE 30 MAY 2026 at 21:30 EEST Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours
LOS ANGELES, May 30, 2026 (GLOBE NEWSWIRE) -- Momcozy, the globally recognized mother-and-baby brand known for its wearable breast pump line, today announced the global launch of Momcozy Plus Baby Wipes. Built around the brand’s “Bring On The Mess” philosophy, the product is designed to give parents the confidence to embrace childhood’s messiest — and…
Pennsylvania, United States, May 30, 2026 (GLOBE NEWSWIRE) -- Healthcare has changed rapidly over the last few years, and many patients now prefer the convenience of online pharmacy services over traditional in-store visits.
Atlanta, GA, May 30, 2026 (GLOBE NEWSWIRE) -- Beauty entrepreneur Mikey Moran has officially launched GLZD, a new men’s grooming brand introducing “body glaze”—a water-free product category designed to combine skincare, fragrance, and skin finish into a single daily routine.
